Opioid Post-marketing Studies: Can Sponsors Work Well Together Again?
Executive Summary
FDA wants to get a handle on how long-term use of long-acting pain killers relates to abuse and misuse; the agency also is requiring labeling changes that remove “moderate” pain from the products’ indication.
You may also be interested in...
Opioid Long-Term Effectiveness: FDA Postmarket Trial Design Offers ‘Best Compromise’
FDA advisory committee to consider proposed protocol to meet postmaketing requirement set a decade ago to determine risk of hyperalgesia following long-term use of ER/LA opioid analgesics. Initial trial was terminated in 2018 due to inability to recruit enough patients.
Endo's Belbuca Is First Buccal Film In Extended-Release Opioid Class
While Belbuca represents a new formulation, it does not contain the abuse-deterrent properties that FDA has been encouraging.
Opioid Prescriber Knowledge Assessment Due Year After Patient Assessment
REMS assessment schedule for the long-acting/extended release opioid products reflects the large number of drugs, prescribers and patients involved in the risk management program and the time needed to put all its components in place.